ASND Earnings Prediction
The chart below shows how ASND performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ASND sees a -1.57% change in stock price 10 days leading up to the earnings, and a +3.82% change 10 days following the report. On the earnings day itself, the stock moves by -0.06%. This data can give you a slight idea of what to expect for the next quarter's release.
ASND Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
57.83M
20.40%
60.66%
Gross Margin
80.63%
-4.72%
18.31%
Operating Margin
-167.28%
-40.22%
-54.81%
Net Margin
-171.52%
-49.21%
-43.55%
EPS
-1.72
-40.28%
-9.95%
No Data Available
ASND Earnings Analysis
Ascendis Pharma A/S American Depositary Shares Corporation (ASND.O) Earnings Conference Call
Positive
Volume Surge in Q3: S K Y T R O F A volume increased more than 60% in the third quarter of 2024, compared to the third quarter last year, while reported revenue was EUR 47.2 million compared to EUR 47 million reported in the third quarter of 2023.
Sales Deductions Impact: The increase in volume was offset primarily by higher sales deductions compared to the prior year as a result of broader market access.
Revenue Decline in Q3: S K Y T R O F A revenue in the third quarter of 2024 related to channel inventory was approximately EUR 3.5 million lower compared to the third quarter last year.
Revenue Increase Overview: S K Y T R O F A revenue for the first nine months of 2024 totaled EUR 138.5 million, a 21% increase year-over-year compared to EUR 114.4 million during the same period in 2023.
Operating Expenses Decrease: Total operating expenses for the third quarter of 2024 were EUR 143.4 million, an 18% decrease compared to EUR 175.1 million during the third quarter of 2023.
Negative
Minimal Revenue Growth: S K Y T R O F A revenue in the third quarter of 2024 was EUR 47.2 million compared to EUR 47 million reported in the third quarter of 2023, indicating minimal growth despite a 60% increase in volume year-over-year.
Sales Deductions Impact: The increase in volume was offset primarily by higher sales deductions compared to the prior year as a result of broader market access.
Channel Inventory Revenue Decline: S K Y T R O F A revenue related to channel inventory was approximately EUR 3.5 million lower compared to the third quarter last year.
Revenue Adjustment Impact: S K Y T R O F A revenue was also negatively impacted by adjustments related to prior period sales deductions of EUR 2.5 million.
R&D Cost Decline: R&D costs in the third quarter of 2024 totaled EUR 73.5 million compared to EUR 111.4 million during the third quarter of 2023, reflecting a 34% decline largely due to lower external development costs.
ASND FAQs
How does ASND typically perform around its earnings report dates?
Is Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ASND Earning Call Sentiment
Ascendis Pharma A/S (ASND) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ASND.O
0.02%Positive
The earnings call summary highlights strong financial performance with reduced R&D expenses and increased cash reserves. The Q&A section reveals confidence in market positioning and breakeven targets, despite some uncertainties. The launch of YORVIPATH in the US and collaboration with Novo Nordisk are potential catalysts. However, concerns about competition and unclear timelines for certain projects are noted. Overall, the market's positive response to the new product launch and strategic partnerships should drive a positive stock price movement over the next two weeks.
